| Literature DB >> 28352339 |
Mehtap Kara1, Eren Ozcagli1, Persefoni Fragkiadaki2, Tugba Kotil3, Polychronis D Stivaktakis2, Demetrios A Spandidos4, Aristides M Tsatsakis2, Buket Alpertunga1.
Abstract
Anabolic androgenic steroids (AAS) are performance-enhancing drugs commonly abused by atheletes. Stanozolol is a synthetic testosterone-derived anabolic steroid. Although it is well known that AAS have several side-effects, there are only few toxicological studies available on the toxic effects and mechanisms of action of stanozolol. The aim of this study was to investigate the genotoxic effects of stanozolol and to determine its effects on telomerase activity in Sprague-Dawley male rats. For this purpose, 34 male rats were divided into 5 groups as follows: i) the control group (n=5); ii) the propylene glycol (PG)-treated group (n=5); iii) the stanozolol-treated group (n=8); iv) the PG-treated group subjected to exercise (n=8); and v) the stanozolol-treated group subjected to exercise (n=8). PG is used as a solvent control in our study. Stanozolol (5 mg/kg) and PG (1 ml/kg) were injected subcutaneously 5 days/week for 28 days. After 28 days, the animals were sacrificed, and DNA damage evaluation (comet assay) and telomerase activity assays were then performed using peripheral blood mononuclear cells (PBMCs). Telomerase activity was measured by using the TeloTAGGG Telomerase PCR ELISA PLUS kit. The results of this study revealed that stanozolol treatment induced DNA damage, while exercise exerted a protective effect. Stanozolol treatment without exercise stimulation was associated with a significant increase in telomerase activity in the PBMCs.Entities:
Keywords: DNA damage; anabolic androgenic steroids; comet assay; stanozolol; telomerase activity
Year: 2016 PMID: 28352339 PMCID: PMC5348646 DOI: 10.3892/etm.2016.3974
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Experimental groups in this study.
| Animal groups[ | No. of rats | Procedures undertaken |
|---|---|---|
| Group I | 5 | No injection, no exercise |
| Group II | 5 | Subcutaneous injection of 1 ml/kg PG |
| Group III | 8 | Subcutaneous injection of 5 mg/kg stanozolol |
| Group IV | 8 | Subcutaneous injection of 1 ml/kg PG, exercise 20 min/day, 5 day/week (swimming) |
| Group V | 8 | Subcutaneous injection of 5 mg/kg stanozolol, exercise 20 min/day, 5 day/week (swimming) |
Group I, control; group II, PG; group III, stanozolol; group IV, PG treatment and exercise; group V, stanozolol treatment and exercise; PG, propylene glycol
Expression of tail intensity and telomerase activity (%) in the peripheral blood mononuclear cells from the rats in the experimental groups.
| Assay | Exposure[ | No. of rats | Mean ± standard deviation | Median | Kruskal-Wallis |
|---|---|---|---|---|---|
| Tail intensity | Group I | 5 | 4.0±0.5 | 4.3 | χ2=10.56 |
| Group II | 5 | 4.8±2.8 | 3.9 | df=4 | |
| Group III | 8 | 5.8±1.6 | 0.5 | P=0.032 | |
| Group IV | 8 | 5.1±1.7 | 4.85 | ||
| Group V | 8 | 3.5±0.6 | 3.6 | ||
| Telomerase activity (%) | Group I | 5 | 100.0±19.4 | 93.3 | χ2=24.65 |
| Group II | 5 | 474.9±358.2 | 597.0 | df=4 | |
| Group III | 8 | 1,851.4±319.2 | 1,909.2 | P<0.001 | |
| Group IV | 8 | 193.4±27.9 | 196.5 | ||
| Group V | 8 | 328.7±183.1 | 240.0 |
Group I, control; group II, PG; group III, stanozolol; group IV, PG treatment and exercise; group V, stanozolol treatment and exercise.
Figure 1.(A) Tail intensity and (B) telomerase activity (%) of stanozolol and propylene glycol (PG)-exposed groups. Group I, control; group II, PG; group III, stanozolol; group IV, PG treatment and exercise; group V, stanozolol treatment and exercise. Extreme outliers are indicated by an asterisk (*) and circle (º).